Benzinga | May 18, 2021 10:45AM EDT

Roth Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $11

Roth Capital maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $12 to $11.